Director, Myeloma Program, USCF
Dr. Wolf established the country’s first community-hospital–based Bone Marrow Transplant unit at Alta Bates Medical Center in Berkeley. While there, he was among the first to study Bortezomib (Velcade) and Lenalidomide (Revlimid) in patients with Myeloma.
In 2007, he joined the faculty at the University of California, San Francisco, where he helped to establish the largest myeloma program on the West Coast. This program currently treats over 2000 active myeloma patients, performs over 120 myeloma stem cell transplants a year, has a robust clinical research program and an extensive laboratory based research program specializing in the development of new drugs for the treatment of Myeloma. Over the last twenty years he has become an internationally recognized opinion leader in the Myeloma field and has continued to treat patients, participate in research studies and speak at numerous meetings around the world.
In addition to his work life, Dr. Wolf has found time to travel extensively, especially in the Himalayas where he has volunteered his time to treat patients at a cancer clinic in Bhaktapur, Nepal. In addition to working there, he has arranged a very large donation of radiation and radiology equipment to help this cancer center.
Throughout his life he has been active in sports, although his days on basketball and tennis courts have given way to hiking all over the world and more recently, increased time on a bicycle seat. He very much looks forward to joining the Myeloma community on its bicycle adventure in the Willamette Valley of Oregon, and especially to join the multiple myeloma connected riders on this important effort to fund myeloma research.
At Janssen Oncology, we’re shaping the future of cancer treatment. In the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson.About Janssen Oncology
Click below to learn more about a treatment option for multiple myeloma. If you’re also interested in getting more information from Janssen, sign up for ongoing communications.Learn More